Recent development of drugs for osteoporosis and anti-cancer agents: a patent analysis

Antibacterial and Antimalarial Therapeutic Agents: A Patent Perspective

BACKGROUND

Antibacterial and antimalarial drugs play a critical role in combating infectious diseases. It is a continuous work to develop new types of antibacterial and antimalarial drugs.

OBJECTIVE

To better understand current landscape and association of antibacterial and antimalarial agents, the European patent analysis was performed.

METHODS

Antibacterial and antimalarial agents were analyzed by patent analysis. Patent documents from January 2003 to May 2022 were retrieved and analyzed.

RESULTS

The present study indicated there were virtually three therapeutic approaches for antibacterial agents, including chemical drugs, biological products and siRNA technology. Chemical drugs were a mainstream therapeutic approach for development of both antibacterial and antimalarial agents. However, the present study found that in contrast to antimalarials, siRNA technology had been initially explored as therapeutic strategy for antibacterial agents. Also, our study is the first to show that there is a low correlation between antibacterial and antimalarial agents.

CONCLUSION

Globally, our study is the first one to show that it may be not a fast approach to discover antimalarial drugs from antibacterial agents based on drug repurposing. siRNA technology as therapeutic strategy had been explored and used in antibacterial field.

Current Status and Patent Prospective of Lipid Nanoparticle for mRNA Delivery

INTRODUCTION

mRNA-LNP delivery is currently a research hotspot in pharmaceutics. Lipid nanoparticle has emerged in pharmaceutical industry as popular and effective vehicles for mRNA delivery. It is therefore significant to understand current landscape and recent development of lipid nanoparticle for mRNA delivery.

AREAS COVERED

This article provides patent landscape and recent development for mRNA-LNP delivery by US-granted patent analysis. The US-granted patents from January 2003 to December 2022 were retrieved and analyzed by using patsnap.

EXPERT OPINION

Globally, the present article was the first one which showed that mRNA-LNP delivery system demonstrated three therapeutic applications including vaccines, anticancer, and diseases associated with protein or enzyme deficiencies. Modernatx is most powerful company, and leads almost all technologies in mRNA-LNP field. In addition, the technologies related to lipid nanoparticle for mRNA delivery are virtually controlled by top three assignees. mRNA-LNP delivery in therapy of diseases associated with enzyme deficiencies may be a future trend. The article provides recent advances in lipid nanoparticle for mRNA delivery.